Samsung Electronics Co., Ltd. invested $175 million in Element Biosciences, Inc.'s upsized Series E financing round, becoming its largest shareholder. The investment, announced on June 9, 2026, strengthens Samsung's relationship with the genomic and multiomic technology company. The transaction is subject to regulatory approvals.

Element Biosciences stated that the proceeds will support commercialization and adoption of its genomic and multiomic solutions, expand its global presence, and advance its product roadmap. Samsung noted that the investment reflects confidence in Element's progress in next-generation sequencing, multiomics, and clinical workflows. The move aligns with Samsung's focus on precision medicine and life sciences innovation.

Greenberg Traurig, LLP advised Samsung on the transaction. The team was led by Shareholder Wayne H. Elowe, co-chair of Greenberg Traurig's Global Life Sciences & Medical Technology Group and co-chair of the firm's Atlanta Corporate Practice. Elowe emphasized the firm's multidisciplinary approach and global platform in delivering seamless legal services.

The Corporate team included Shareholders Kyle (Gyuil) Oh in Singapore and Seoul, and Brian L. Petrequin in New Jersey. Associates Brian J. Landau, William H. Grossenbacher, Mary Kathryn Cicchillo, and Sophia A. Korn in Atlanta, and Associate Alex (Yongsun) Kwon in Seoul also participated. The team was supported by attorneys from various practice areas, including Intellectual Property & Technology, Health Care & FDA Practice, Labor & Employment, International Trade, Antitrust Litigation & Competition Regulation, Real Estate, and Data Privacy & Cybersecurity.